NCT05469919View on ClinicalTrials.gov

An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 9, 2022

Primary Completion Date

August 17, 2023

Study Completion Date

March 12, 2024

Conditions
Advanced Solid Malignancies
Interventions
DRUG

Ceralasertib

Ceralasertib taken orally

Trial Locations (1)

104-0045

Research Site, Chūōku

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY